Federal Register Notice: FDA’s Arthritis Advisory Committee will meet 5/8, from 8:30 a.m. to 5 p.m.
at FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss Regeneron Pharmaceuticals’ supplemental BLA for Arcalyst (rilonacept) injection to prevent gout flares during initiation of uric-acid lowering therapy in adult patients with gout. Contact Philip Bautista, (301) 796-9001. To view this notice, click here.